

Substitute for form 1449A/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			
Complete if Known			
Application Number		10/509,009	
Filing Date		May 3, 2005	
First Named Inventor		Chiquet-Ehrismann et al.	
Art Unit		1643	
Examiner Name		Anne Gussow	
Sheet	1	of	1
Attorney Docket No: FM-05-US			

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T ²

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/AMG/		REARDON, DAVID A. et al., Phase II Trial of Murine ¹³¹I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas; Journal of Clinical Oncology, Vol 20; No 5; pp 1389-1397; March 1, 2002.			

EXAMINER

/Anne M. Gussow/

DATE CONSIDERED

04/30/2009